CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0422 (clinicaltrials.gov NCT No: NCT00254423)
Title:Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Dasatinib (BMS-354825)
Principal Investigator:Jorge Cortes
Treatment Agent:BMS-354825
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if BMS-354825 (dasatinib)
can help to control CML in chronic phase. The safety of this drug will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:BMS-354825
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:None anticipated
Supported By:N/A
Return Visit:Every 3-4 months for 1 year, then every 6-12 months.
Home Care:Medication is self-administered (orally)


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults